ClinicalTrials.gg
RecruitingNCT04263285Updated Nov 17, 2026

Treatment of Depression Post-SCI

An interventional study of rTMS in Depression and Spinal Cord Injuries, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Depression by Medical University of South Carolina — 17 open to participants now, 21 under way, none of them phase 3. Depression · Medical University of South Carolina.

Planned enrollment
39th of 45
14 · median 46
Started
2027
with 1 other
No phase
31 of 47
13 open now
Primary completion
2029-09
later than 20 of 20 live
Registered
20th of 47
by date

Among the 47 studies in Depression by Medical University of South Carolina, this one is the 39th largest by planned enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2027, is one of 31 with no phase, reaches primary completion later than 20 of the 20 other live ones, and was the 20th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

17 of the 47 studies in Depression by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Depression by Medical University of South Carolina, or all of them as a file.
02

Study summary

Depression is more common after a spinal cord injury (SCI) than in the general population. Unfortunately, it is unknown how depression is typically treated in individuals with SCI or if commonly used treatment methods are effective. This study will investigate the safety and impact of a novel method for treating depression called repetitive transcranial magnetic stimulation (rTMS). rTMS is a type of non-invasive brain stimulation. Fourteen individuals with a cervical or thoracic level SCI and depression will complete an approved treatment plan using rTMS. Participants will be treated using rTMS five days a week for four weeks. After four weeks of treatment, the study team will review the safety of rTMS and assess changes in depressive symptoms. If the results are positive, larger studies can be designed to develop better treatment options for individuals with SCI and depression.

03

Conditions studied

  • Depression
  • Spinal Cord Injuries
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 - 70;
  2. At least 6 months post incomplete cervical or incomplete or complete thoracic level SCI;
  3. Have at least partial active movement of the right thumb (abductor pollicis brevis) to allow for FDA approved rTMS dosing;
  4. Major depressive disorder, as identified through screening tools;
  5. No antidepressant medications or no change in doses of psychotropic medication(s) for at least 4 weeks prior to the study (6 weeks if newly initiated medication).

Exclusion criteria

Exclusion criteria:

  1. Concomitant neurologic diseases/disorders or dementia;
  2. Cognitive impairment, as identified through a screening tool ();
  3. History of major head trauma as identified through a screening tool (Ohio State University Traumatic Brain Injury Identification Method);
  4. History of psychosis or other Axis I disorder that is primary;
  5. Positive screen for bipolar disorder, as identified through a screening tool (The Mood Disorder Questionnaire);
  6. \<1 year;
  7. Attempt of suicide in the last 2 years;
  8. Electronic or metallic implants (i.e. metal in the head, cochlear implant, or pacemaker);
  9. History of seizures or currently prescribed anti-seizure medications;
  10. Taking medication that increases the risk of seizures;
  11. Pregnancy as identified through a positive pregnancy test;
  12. Inability or unwillingness of subject or legal guardian/representative to give .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    rTMS (Repetitive Transcranial Magnetic Stimulation)

    Device: rTMS

Interventions

  • DevicerTMS

    The study team will deliver rTMS five days a week for four weeks, according to a specific and approved protocol for participant positioning, motor threshold determination, and dosing.

06

What researchers measure

Primary outcomes

  1. Safety as assessed by number of adverse events

    Report of adverse and serious adverse events in all participants.

    Time frame: Through the study period (5 weeks)

  2. Number of visits missed

    The average of the number of intervention visits missed across all participants

    Time frame: Throughout the treatment period (4 weeks)

  3. Change in depressive symptoms as assessed by the Hamilton Rating Scale for Depression

    The Hamilton Rating Scale for Depression consists of 17 questions with a total score range from 0 - 52. Ranges of total score include the following: 0 - 7 suggests normal/no depressive symptoms; 8 - 16 suggests mild depressive symptoms; 17 - 23 suggests moderate depressive symptoms; and 24 - 52 suggests severe depressive symptoms.

    Time frame: Baseline, midpoint (Week 3), and post treatment (5 weeks)

Secondary outcomes

  1. Change in depressive symptoms as assessed by the Montgomery- Asberg Depression Rating Scale (MADRS)

    Montgomery- Asberg Depression Rating Scale consists of 10 questions with a range of 0 - 60. Ranges of total score include the following: 0 - 6 suggest normal/ no depressive symptoms; 7 - 19 suggests mild depressive symptoms; 20 - 34 suggests moderate depressive symptoms; and 34 - 60 suggests severe depressive symptoms.

    Time frame: Baseline, midpoint (Week 3), and post treatment (5 weeks)

  2. Change in the impact depressive symptoms have on one's life as assessed by the Sheehan Disability Scale.

    The Sheehan Disability Scale is a self-report questionnaire that assess how depressive symptoms have impacted one's ability to participate in work/school, social life, and family life. Each question is scored from 0 (not at all) to 10 (extremely). Total score ranges from 0 (unimpaired) to 30 (highly impaired).

    Time frame: Baseline, midpoint (Week 3), and post treatment (5 weeks)

  3. Change in subjective well-being based on the Satisfaction With Life Scale.

    The Satisfaction With Life Scale is a self-report questionnaire regarding subjective well-being. The scale consists of 5 questions that are rated between 1 (Strongly Disagree) to 7 (Strongly Agree). Pre and post intervention answers will be compared.

    Time frame: Baseline and post treatment (5 weeks)

  4. Change in physical activity based on the Leisure Time Physical Activity Questionnaire for People with Spinal Cord Injury

    Self-report questionnaire regarding the number of days and minutes an individual participates in mild, moderate, and heavy intensity physical activity/effort. Pre and post intervention answers will be compared.

    Time frame: Baseline and post treatment (5 weeks)

  5. Change in function as assessed by the Spinal Cord Independence Measure III-Self Report.

    The Spinal Cord Independence Measure III-Self Report is a self-report questionnaire regarding the degree of assistance needed for daily self care activities, such as eating, bathing, dressing, grooming, breathing, bladder and bowel management, toileting, transfers, and mobility. There are a total of 17 questions with a total score of 0 (assistance required) to 100 (no assistance or mobility aids). Pre and post intervention scores will be compared.

    Time frame: Baseline and post treatment (5 weeks)

  6. Change in function and daily activities as assessed by the Craig Handicap Assessment and Reporting Tool-Short Form

    The Craig Handicap Assessment and Reporting Tool-Short Form is a self-report questionnaire that includes a total of 19 questions regarding physical assistance, cognitive assistance, mobility, occupation, social integration, and financial resources. Pre and post intervention answers will be compared.

    Time frame: Baseline and post treatment (5 weeks)

  7. Change depressive symptoms as assessed by the Patient Health Questionnaire-9 score

    The Patient Health Questionnaire-9 is a 9 questions self-report measure of depressive symptoms. The total score ranges from 0 - 27. Ranges of total score include the following: 0 suggests no depressive symptoms; 1 - 4 suggests minimal depressive symptoms; 5 - 9 suggests mild depressive symptoms; 10 - 14 suggests moderate depressive symptoms;15 - 19 suggests moderately severe depressive symptoms; and 20 - 27 suggests severe depressive symptoms.

    Time frame: Baseline, midpoint (Week 3), and post treatment (5 weeks)

07

Study locations

1 of 1 sites recruiting
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Catherine VanDerwerker, DPT, PhD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Sep 2029, 28 months later.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 28 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → May 2027, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2020
First posted
Feb 10, 2020
StartEst.
May 2027was Oct 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→May 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Start date Oct 2026→May 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04263285
Collaborators
The Craig H. Neilsen Foundation
Responsible party
Catherine VanDerwerker (Research Associate, Medical University of South Carolina) — Principal investigator
First posted
Feb 10, 2020
Start date
May 2027 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Catherine VanDerwerker, DPT, PhD
Contact
vanderwe@musc.edu
843-792-5047
Catherine VanDerwerker, DPT, PhD
principal investigator · Medical University of South Carolina

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion